Bevacizumab (BEV), a monoclonal IgG antibody that inhibits angiogenesis by binding and neutralizing vascular endothelial growth factor A (VEGF-A), leads to the restoration of effective anti-tumor immunity by reducing the circulating S100A9-positive myeloid-derived suppressor cells; thus, extended progression-free survival and protected against brain metastasis in patients with EGFR-mutant lung adenocarcinoma [161]. The gene discussed is S100A9; the disease is neoplasm.